Therapeutic Effect of Extracellular Vesicles Derived from HIF Prolyl Hydroxylase Domain Enzyme Inhibitor-Treated Cells on Renal Ischemia/Reperfusion Injury
Introduction: Acute kidney injury (AKI) is a major public health problem worldwide. However, there is no definitive therapies to treat established AKI. In this study, we used FG-4592 to induce hypoxia inducible factor (HIF) expression in cells and then explored whether the extracellular vesicles (EV...
Saved in:
Main Authors: | Zhao-Ying Ding (Author), Tao-Tao Tang (Author), Zuo-Lin Li (Author), Jing-Yuan Cao (Author), Lin-Li Lv (Author), Yi Wen (Author), Bin Wang (Author), Bi-Cheng Liu (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
by: Andrey A. Poloznikov, et al.
Published: (2021) -
Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020) -
Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
by: Yu-Hsiang Chou, et al.
Published: (2023) -
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023) -
Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism
by: Matthew Riopel, et al.
Published: (2020)